This content is from: Premium

Could Merck Become an Activist Target? One Hedge Fund Thinks So

Suvretta Capital Management — which is not an activist investor — lays out the case in its second quarter letter.

Is Merck an attractive target for activists?At least one hedge fund firm thinks so.In its second-quarter letter, dated August 17 and obtained by Institutional Investor, Suvretta Capital Management — which is not an activist hedge fund — makes the case for the drug giant winding up in the cross-hairs of

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content